Alpha 2.0
Login Register
» Authors » I Vergote

I Vergote

Explore the profile of I Vergote including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 260
Citations 5744
Followers 0
Related Specialties
Oncology
Gynecology & Obstetrics
General Medicine
Top 10 Co-Authors
F Amant
P Neven
D Timmerman
P Berteloot
K Leunen
P Moerman
B Van Calster
H Wildiers
A du Bois
J Sehouli
Published In
Ann Oncol
Gynecol Oncol
Int J Gynecol Cancer
Eur J Cancer
Ultrasound Obstet Gynecol
Affiliations
Soon will be listed here.
Recent Articles
1.
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
Harter P, Marth C, Mouret-Reynier M, Cropet C, Lorusso D, Guerra-Alia E, et al.
Ann Oncol . 2024 Nov; 36(2):185-196. PMID: 39528049
Background: The use of first-line poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is increasing in advanced ovarian cancer. Understanding the efficacy of first subsequent therapy (FST) in patients experiencing disease progression...
2.
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Monk B, Barretina-Ginesta M, Pothuri B, Vergote I, Graybill W, Mirza M, et al.
Ann Oncol . 2024 Sep; 35(11):981-992. PMID: 39284381
Background: The phase III PRIMA/ENGOT-OV26/GOG-3012 trial met its primary endpoint. Niraparib first-line maintenance significantly prolonged progression-free survival (PFS) among patients with newly diagnosed advanced ovarian cancer that responded to first-line...
3.
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
Ledermann J, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, et al.
Ann Oncol . 2024 Feb; 35(3):248-266. PMID: 38307807
The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June...
4.
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
Pujade-Lauraine E, Selle F, Scambia G, Asselain B, Marme F, Lindemann K, et al.
Ann Oncol . 2023 Oct; 34(12):1152-1164. PMID: 37797734
Background: Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is the standard of care for some patients with advanced ovarian cancer. We evaluated the efficacy and safety of PARP inhibitor rechallenge. Patients...
5.
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
Ray-Coquard I, Leary A, Pignata S, Cropet C, Gonzalez-Martin A, Marth C, et al.
Ann Oncol . 2023 May; 34(8):681-692. PMID: 37211045
Background: In the PAOLA-1/ENGOT-ov25 primary analysis, maintenance olaparib plus bevacizumab demonstrated a significant progression-free survival (PFS) benefit in newly diagnosed advanced ovarian cancer patients in clinical response after first-line platinum-based...
6.
Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer
Vergote I, Van Nieuwenhuysen E, Casado A, Laenen A, Lorusso D, Braicu E, et al.
Gynecol Oncol . 2023 May; 174:80-88. PMID: 37167896
Objective: Nintedanib is an oral tyrosine kinase inhibitor targeting, among others, vascular endothelial growth factor receptor. The aim was to establish the role of nintedanib in addition to paclitaxel and...
7.
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12...
Colombo N, Gadducci A, Sehouli J, Rulli E, Maenpaa J, Sessa C, et al.
Br J Cancer . 2023 Feb; 128(8):1503-1513. PMID: 36759720
Background: This trial investigated the hypothesis that the treatment with trabectedin/PLD (TP) to extend the platinum-free interval (TFIp) can improve overall survival (OS) in patients with recurrent ovarian cancer (OC)....
8.
Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis
Labidi-Galy S, Rodrigues M, Sandoval J, Kurtz J, Heitz F, Mosconi A, et al.
Ann Oncol . 2022 Dec; 34(2):152-162. PMID: 36564284
Background: In the phase III PAOLA-1 study, the addition of maintenance olaparib to bevacizumab in patients with newly diagnosed high-grade ovarian cancer (HGOC) resulted in prolonged progression-free survival (PFS), particularly...
9.
Benign descriptors and ADNEX in two-step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohort
Landolfo C, Bourne T, Froyman W, Van Calster B, Ceusters J, Testa A, et al.
Ultrasound Obstet Gynecol . 2022 Sep; 61(2):231-242. PMID: 36178788
Objective: Previous work has suggested that the ultrasound-based benign simple descriptors (BDs) can reliably exclude malignancy in a large proportion of women presenting with an adnexal mass. This study aimed...
10.
Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe
Van der Kolk W, van der Zee A, Slomovitz B, Baldwin P, van Doorn H, de Hullu J, et al.
Gynecol Oncol . 2022 Sep; 167(1):3-10. PMID: 36085090
Objective: Optimal management of the contralateral groin in patients with early-stage vulvar squamous cell carcinoma (VSCC) and a metastatic unilateral inguinal sentinel lymph node (SN) is unclear. We analyzed patients...